of 73 windows beat the index

What this strategy is
Carnelian Capital Compounder Fund 1 is a moderate PMS strategy from Carnelian Capital. It follows a Value style, is benchmarked to the S&P BSE 200 Index, and carries a Nyra score of 8.9 out of 10.
- This strategy₹3.89 Cr
- S&P BSE 200 Index₹2.24 Cr
Illustrative monthly path, net of fees, modelled to the strategy's since-inception CAGR versus the S&P BSE 200 Index. Not the actual NAV series; past performance is not indicative of future returns.
Trailing returns vs benchmark
Absolute for windows under a year, annualised (CAGR) beyond. Alpha is the strategy minus its benchmark.
This strategyHow often it has beaten the index
Across every rolling holding period in the modelled history — the longer you hold, the more the odds have favoured the strategy.
of 49 windows beat the index
of 25 windows beat the index
of 1 windows beat the index
Computed on an illustrative monthly path modelled to the since-inception CAGR — not the actual NAV series.
The quality of those returns
Returns mean little without the ride that earned them.
In its worst stretch the strategy fell −16.69% peak-to-trough. A Sharpe of 1.15 means it earned a healthy return for each unit of risk taken. Size the position so a drawdown of that order is one you can sit through.
Under the hood — where the money sits
Spread across the market-cap curve.
- Large16%
- Mid84%
Top holdings and the sector book stream from the live feed — ask Nyra for the current portfolio.
Who runs the money
A strategy is only as good as the hand on the wheel.
Carnelian Capital's Moderate approach leans on valuation discipline — buying solid businesses for less than they are worth and waiting for the gap to close. It is benchmarked to the S&P BSE 200 Index but invests with conviction rather than hugging the index.
A focused book of roughly 30–40 holdings means the highest-conviction ideas actually move the portfolio.
A 7-year track record across rallies and drawdowns — positioning shifts with the cycle rather than chasing the last quarter.
Drawdowns are managed deliberately; the worst peak-to-trough on record is about −16.69%.
A high-conviction moderate strategy with a strong scorecard.
Nyra scores Carnelian Capital Compounder Fund 1 8.9/10, on a since-inception CAGR near 21.4% and a 3-year CAGR of 29.9%. Its sharpest fall on record is about −16.69% — size the position so that ride is one you can hold.
Investors with a 5-year-plus horizon who want active Moderate exposure and can sit through equity drawdowns.
A −16.69% drawdown would test your nerve, or you need ₹50 L+ to commit at the SEBI minimum.
A steadier core (large-cap or hybrid) so this can play the higher-conviction satellite in your overall allocation.
The fine print, in plain sight
- Inception
- May 2019
- Track record
- 7 years
- Category
- Moderate
- Style
- Value
- Benchmark
- S&P BSE 200 Index
- Holdings
- —
- Fixed fee
- —
- Performance fee
- Performance-linked
- Minimum investment
- ₹50 L
- Lock-in / exit
- Exit Load: 1 Year: No Option, 2 Year: No Option, 3 Year: No …
- Reporting
- Monthly + live login
- Regulator
- SEBI-registered PMS
PMS Sahi Hai is a SEBI-registered platform. Figures are sourced from the strategy's disclosures and the live feed; the growth chart, rolling-window and risk figures are modelled to the disclosed since-inception CAGR (illustrative, not the actual NAV series). Returns are net of fees where stated. Investments in PMS, AIF and GIFT City strategies are subject to market risk — past performance is not indicative of future results. This page is information, not investment advice.
“I held two PMS for four years and couldn't tell you why. One 15-minute review showed me the overlap, the real post-tax number, and one fund worth replacing. Nobody had ever shown me that math.”
Composite client stories — names changed, numbers preserved.
Carnelian Capital Compounder Fund 1 — common questions
What is Carnelian Capital Compounder Fund 1?
Carnelian Capital Compounder Fund 1 is a Moderate PMS strategy from Carnelian Capital. It follows a Value style, is benchmarked to the S&P BSE 200 Index, and carries a Nyra score of 8.9/10.
Who should consider Carnelian Capital Compounder Fund 1?
It suits investors with a five-year-plus horizon who want active Moderate exposure and can stay invested through market drawdowns. The SEBI minimum is ₹50 L.
What returns has it delivered?
Since inception (May 2019) it has compounded at roughly 21.4% a year, with a 3-year CAGR of 29.9% against 12.9% for the S&P BSE 200 Index. Returns are net of fees; past performance is not a guarantee of future results.
What are the fees and lock-in?
—, with a performance fee of Performance-linked. Exit / lock-in terms: Exit Load: 1 Year: No Option, 2 Year: No Option, 3 Year: No ….
How risky is it?
Like all market-linked products it can fall in value; the worst drawdown on record is about −16.69%. Carnelian Capital is SEBI-registered and reports monthly. This page is information, not investment advice.
